It's fraudulent for academics to give their names to medical
articles ghostwritten by pharmaceutical industry writers, say two Canadian law
professors who call for potential legal sanctions.
Studies suggest that industry-driven drug trials and
industry-sponsored publications are more likely to downplay a drug's harms and
exaggerate a drug's virtues, said Trudo Lemmens, a law professor at the University
of Toronto. The integrity of medical research is also harmed by ghostwritten
articles, he said.
Ghostwriting is part of marketing that can distort the
evidence on a drug, Lemmens said. Industry authors are concealed to insert
marketing messages and academic experts are recruited as "guest"
authors to lend credibility despite not fulfilling criteria for authorship,
such as participating in the design of the study, gathering data, analyzing the
results and writing up of the findings. (Más)
No hay comentarios:
Publicar un comentario